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Background: The transition from pediatric to nephrology care is not yet a standardized procedure. The result is an
increased risk of deteriorating transplant function, with the potential for premature transplant failure.
Methods/Design: In phase I of this study, we shall evaluate the current patient transition situation in all existing
German pediatric and nephrology departments (n = 17), including an evaluation of the views of physicians, nurses,
and psychosocial support staff regarding transition. Phase II will be a prospective, randomized study in which we
compare current unstructured transition (control group) to structured transition (intervention group). The structured
transition approach integrates the core elements of the Berliner TransitionsProgramm in combination with two
facilitating smartphone apps. The primary endpoint of this study will be therapy adherence, as reflected by group
variation coefficients of immunosuppressive agent levels. As a secondary outcome, we will compare patients’
self-reported quality of life, satisfaction of patients and their parents with each transition model, and how
patient-centered healthcare components are utilized. These secondary parameters will be assessed with established
instruments or with instruments developed (and pilot tested) in phase I of the project.
Discussion: The long-term goal of this work is to provide a model of structured transition from pediatric to adult
care for adolescent nephrology patients, in order to improve transplant survival and patient wellbeing.
Trial registration: Identifier: Clinicaltrials.gov: ISRCTN22988897, registered on 24 April 2014).
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The transition of chronically ill adolescents from pe-
diatric to adult medicine should conserve or improve
their state of health. Such a transition can be considered
successful if it promotes the patients’ health competence,
supports their psychosocial rehabilitation, and improves
their self-determination efficacy, including their ability* Correspondence: Kreuzer.Martin@mh-hannover.de
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unless otherwise stated.to make decisions and communicate about their care.
The overarching goal of transition is to enable patients
to be as independent as possible and have the best possible
quality of life. Achieving these goals requires, in addition
to addressing medical issues, a multidimensional, multi-
disciplinary approach, including critical interventions in
psychosocial, school-related, and occupational spheres [1].
Historically, a lack of cooperation among the various
professionals involved in treatment and concomitant
care has led to medical care issues for patients, which is
particularly problematic in the transition phase. From an. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tegies for establishing a satisfactory patient-centered
transition [1-4].
In nephrology in particular, the transition constitutes an
important intersection in patient care [5,6]. More trans-
planted kidneys are lost in patients aged between 16 and
21 years than in any other age group. Such graft failure re-
quires a return to compulsory dialysis, which reduces qua-
lity of life and leads to considerable additional healthcare
expense. Moreover, early graft losses increase mortality
and shorten life expectancy. Some single-center transition
models with transitional or adolescence-centered consul-
ting hours (such as the Nephrology adolescent outpatient
clinic of the Kuratorium for Dialysis and Transplantation
in Hannover) have been established. They represent a new
structural model for medical care in which there is a focus
on prevention of non-adherence to reduce deterioration of
kidney graft failure and, therefore, kidney diseases in this
vulnerable age group [7,8]. Training programs, such as
‘Finally Grown Up’ (‘Endlich-Erwachsen’) [9] and computer-
based training courses [10], have been shown to produce
some improvements in the transition of post-kidney trans-
plant adolescents into adult medical care. For instance,
the positive effects of ‘patient empowerment’ have been
reported for adolescents receiving hyperphosphatemia
therapy [11]. At present, it is not clear which, if any, tran-
sition models are applied in German pediatric nephrology
centers.
The Berliner TransitionsProgramm is the first struc-
tured transition program in Germany to be financed by
statutory health insurance (Figure 1). It regulates the tran-
sition of adolescents with different indications (currently,
diabetes mellitus type 1, epilepsy, renal diseases, juvenileFigure 1 Structure of the Berliner transitions programm. eCRF, electrorheumatoid arthritis, inflammatory bowel diseases, and
neuromuscular diseases) from pediatric to adult medicine
over a period of two years. The program outlines the ways
in which the course of this transition should proceed.
Above all, it contains specific transitional measures for
in-depth communication between the pre- and post-
transition treating physicians, as well as conversations
with adolescent patients and their parents, structured in
terms of time and content. A case management protocol
is used to support and ensure the unhindered flow of in-
formation and application of treatment measures [12].
The introduction of smartphone apps, which can be
used to help monitor adolescent patients, may improve
their adherence [13]. The rationale for using such apps
is to interact with the patients through media that are
familiar to them, enabling them to manage their disease
even under the challenging conditions of adolescence. A
willing acceptance of such high-tech instruments by
adolescent patients can support and develop their com-
petency in dealing with the disease.
We hypothesize that a structured transition, namely
the Berliner TransitionsProgramm, complemented by
telemedicine monitoring via smartphone apps, can facili-
tate the transition to adult care and improve the thera-
peutic adherence of adolescent patients living with a
transplanted kidney. If correct, such an approach would
improve post-transplant functioning and survival, and
ultimately improve patient survival and wellbeing.
In this study, therefore, our first aim is to examine
how many pediatric nephrology centers in Germany em-
ploy a structured transition protocol, and if so, at what
point it is initiated. We are documenting the structure
of transition plans, including courses of action, the typenic case form.
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or case managers), and the financing of programs based
on the study by Bethe and Haffner [14]. In centers with-
out a structured transition protocol, we aim to explore
how transitions are organized and why no transition
program has yet been initiated. Firstly, we will compare
how on-site staff evaluate structured versus unstructured
transition of kidney-transplanted adolescents to adult
medicine and will conduct surveys on the need for pos-
sible improvements. Secondly, by implementing a pro-
spective, multicenter two-arm randomized intervention
study, we plan to clarify whether a structured transition
program with supplementary smartphone apps can im-
prove the outcome of transitioning patients.
Methods/Design
Subjects
The study was approved by the research ethics commit-
tee of the Hannover Medical School (approval number:
6660). Informed consent will be obtained from the ado-
lescent patients, as well as from their parents. The study
cohort will include male and female patients who have
undergone a kidney transplant who were between 16
and 22-years-old at study enrollment. There is a huge
variation in age at transition in Germany; several centers
make the transfer at 18 years whilst others do not trans-
fer until the age of 22. For inclusion the patient must be:
at least 14 months away from expected transfer to adult
medical care, at least three months post-transplantation,
capable of operating a smartphone, and able to provide
informed consent. Exclusion criteria are: signs of acute
transplant rejection or indications of a need for dialysis
in the foreseeable future (since transplant survival is a
study outcome variable), as well as mental incapacity
(since it may prevent complete and independent use of
the apps). Patients will be randomized into two groups:
an intervention group that receives case management by
the Berliner TransitionsProgramm, which is supported
by a smartphone (Samsung Galaxy Y, Samsung, Seoul,
South Korea) with two apps; and a control group trans-
ferred according to the established protocols of the center.
There are centers in Germany which already practice
some kind of transition management, however, no center
actually uses smartphone apps or case management. Our
interventions can also therefore improve outcome in cen-
ters that already practice active transition. Because of the
center-based stratification used in this study, patients from
German centers actually performing transition will be dis-
tributed equally amongst both groups.
Sample size calculation
We first estimated the likely therapy adherence rate based
on a small group of patients on immunosuppressive the-
rapy. Data from Hannover Medical School showed thatamong six selected patients, three showed very good com-
pliance, with a mean coefficient of variation (%) of 0.13
(±0.03), whereas poor compliance was observed in the
three remaining patients, with an average coefficient of
variation (%) of 0.5 (±0.03). These values were taken as
roughly predictive of the variance we would observe in
our study. We will receive additional data from phase I on
which to base the sample size assumptions. Assuming a
population of 50% with very good compliance, 25% with
average compliance, and 25% with poor compliance, we
simulated a mixed distribution with the statistical values
above and calculated an average coefficient of variation
(%) of 0.26, with a standard deviation of 0.15. Our expec-
tation is that the intervention will increase the ratio of pa-
tients with good compliance. For that reason we assumed
the following positively shifted distribution (%) for the
intervention group: 70:30:0 of very good:average:poor
compliance. This distribution corresponds to a coefficient
of variation (%) of 0.181 with the same standard deviation
of 0.15. Assuming a two-sided type I error of 5%, a
Student’s two-sample t-test will have 80% power under the
planning assumptions if n = 57 patients per group are ran-
domized. Hence, a total of 114 patients must be recruited
for this trial. We supposed a negligible dropout rate since
it is critical that transplant patients receive ongoing care
and attend their treatment centers regularly. In addition,
we believe that providing free smartphones will increase
adherence. In the unexpected case of too many dropouts,
we will extend the recruitment phase to ensure sufficient
patients are included in the trial throughout the complete
follow-up period.
Study design
The study is a composite of two phases, as shown in
Figure 2. In phase I, which is currently ongoing, we are
conducting retrospective and prospective structured data
collection and data analysis of the present medical care
situation and care providers’ assessments of it. The pro-
gress of patients who have been transferred within the last
three years and have been receiving medical treatment for
at least a year are being collected in a retrospective anon-
ymized manner and evaluated. Additionally, we are devel-
oping and piloting data collection tools (questionnaires,
interview guidelines, and smartphone apps) for phase II of
the study, which consists of an open, prospective, multi-
center two-arm, randomized intervention analysis.
Phase I
A retrospective analysis of the existing structures is car-
ried out on-site at each of 17 pediatric nephrology centers,
together with prospective questioning to assess the transi-
tion mechanisms. We follow a structured analysis of the
existing transition procedures (initiation, beginning, finan-
cing, participants, documentation, and experiences) and
Figure 2 Overview of study milestones, phases, and timeline.
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tional transition protocols based on qualitative (personal)
expert surveys. Healthcare provider assessments include
three interviews: one with a physician at each center, one
with each center’s auxiliary nursing unit, and one with
each center’s psychologist or social worker. The interviews
are being analyzed in following recommendations made
by Mayring [15] to define ways of recruiting subjects for
the prospective study.
Information regarding each patient’s medical care and
treatment course are registered via an anonymized ques-
tionnaire for patients who transferred in the years 2011
and 2012 from all of the participating pediatric neph-
rology centers, covering before and after the transfer.
Treatment course variables include estimated glomerular
filtration rate (eGFR), coefficient of variation (%) of im-
munosuppressive levels, and incidence of acute rejection
and transplant loss. Additionally, an online transition
questionnaire for physicians and nephrologists is being
developed; it will be distributed by the German Society
for Nephrology.Transfer supporting apps
We will employ apps designed to support the documenta-
tion and transfer of clinical data and to facilitate appoint-
ment scheduling. The apps are being developed for iOS and
Android smartphones, with a diary function in cooperation,
with the Children’s Aid Association for Organ Transplant-
ation - Sportsmen for Organ Donation Registration Society
(‘Verein Kinderhilfe Organtransplantation - Sportler für
Organspende e.V.’ (KiO)). There is a pre-existing app
that, in conjunction with KiO, is being extended for
monitoring of clinical values (Kinderhilfe Organtrans-
plantation, Frankfurt, Germany). In addition, a new app
to organize appointments and communicate with the
case manager will be developed to complement theBerliner TransitionsProgramm (Synectic, Berlin, Germany).
The apps are currently being piloted with some patients.Phase II
Phase II of the study will be a real world, prospective,
multicenter, randomized two-arm intervention, in which
an intervention and a control group will be compared.
In the control group, adolescents will go through transi-
tion as established in their center. In the intervention
group, adolescents will be transitioned using structural
elements from the Berliner TransitionsProgramm (case
manager, transition interviews, and so forth) and with
the smartphone apps developed during phase I.
An on-site physician involved in the study will obtain
consent from patients that meet the inclusion and exclu-
sion criteria, and also from parents for patients under
18 years of age. Patients will be enrolled at least 14 months
before the study termination point and will be randomized
into intervention and control groups. Identification of eli-
gible patients began in the first year of the study. The
physician continuing with each patient’s medical care will
be identified and contact will be established with all re-
ceiving physicians for both study groups. Patient and
physician addresses are also being registered so that,
should there be a change in care providers, contact can be
maintained. Patients and family members will be inter-
viewed at two time points using standardized instruments
for collecting personal data; these are being developed in
phase I of the study. If necessary, available validated tools
will be adapted.Time points
The phase II study timeline, summarized in Figure 3,
begins with the start of transition and concomitant entry
(E) into the study at time point T0 (baseline), and pro-
ceeds with a 12-month assessment at time point T1 and
Figure 3 Structure of the intervention study (Phase II).
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collect data for each group about each patient’s expecta-
tions for the transition, health status, time since trans-
plantation, quality of life, satisfaction with medical care,
therapy, adaptation to the disease, healthcare utilization,
social environment, education, gender, age, and number
of siblings. At T1, both groups will be evaluated for the
transition planned, health status, quality of life, satisfac-
tion with medical care, healthcare utilization, therapy
system, and adherence. The intervention group will also
be asked additional questions at T1 regarding their ex-
perience with the smartphone and app and how well
they have adopted the program. After the T1 evaluation,
each patient will be transferred to their respective adult
care nephrologist. The following variables will be as-
sessed at T2: evaluation of the transition, health status,
quality of life, satisfaction with medical care, healthcare
utilization, therapy system, education, employment, rela-
tionship status, and adherence.
Baseline data will be documented once, retrospectively.
The course of immunosuppressive agent levels and eGFR,
the number of acute rejection reactions (examined every
four to eight weeks), and eventually the detection of
donor-specific antibodies if evaluated by the nephrologist,
will be recorded as surrogate parameters of therapy ad-
herence. This diagnostic schedule is in accordance with
standard German healthcare and would be followed re-
gardless of participation in the study. No blood sampleswill be collected in addition to those collected in the nor-
mal course of care. Necessary data will be extracted retro-
spectively from patient files and added to the electronic
clinical record file during the study.
Protection against bias
Firstly, this is a prospective, randomized, intervention
study. Secondly, patients are being assigned to groups by
block randomization with a variable block length. Ran-
domization will be performed for the most important
prognostic factors, namely center, gender, and time after
transplantation (less than five years or five years or
more). The stratification for center will ensure that for
both centers with and without experience in transition
patients will be enrolled randomly to both groups. In
this way, it will also ensure that the different approaches
used in adult centers after transition will be distributed
equally in both groups. Thirdly, the costs for the Berliner
TransitionsProgramm are being absorbed for those pa-
tients whose health insurance company refuses to cover
the costs. For all other patients, the costs will be regu-
lated by health insurance.
Study endpoints
The long-term goal of this work is to improve adherence
through a controlled transition process. The primary out-
come variable of the study is therapy adherence, as
indicated by individual variability in immunosuppressive
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corded at all regular follow-up examinations (every four to
eight weeks). A coefficient of variation (%) will be calcu-
lated for each patient based on these examination data.
These coefficient values will serve as a surrogate param-
eter for patient adherence. The individual coefficient of
variation (%) for immunosuppressive agent levels is the
endpoint of choice for this field of research [15].
The secondary endpoints of the study are change in
pre- and post-transfer eGFR (using the Schwartz 2009
formula [16], Modification of Diet in Renal Disease
formula [17], and cystatin-C levels), serum creatinine
levels, transplant survival, patient survival, acute rejec-
tion reactions (presence of donor-specific antibodies and
chronic-humoral rejection), transplant loss, death, pa-
tient satisfaction, healthcare utilization, and patients’
self-reported quality of life and social integration.
Statistical analysis
The coefficients of variation (%) for immunosuppressive
agent levels will be analyzed by analysis of covariance, with
adjustment for immunosuppressive agent level at T0 and
all stratification variables considered in the randomization,
such that the analysis of covariance can be used to deter-
mine group differences. [18] Least squares means will be
calculated for each group and the difference between the
group means will be reported with a two-sided 95% confi-
dence interval (CI). If the upper limit of the CI for the dif-
ference between the adjusted means (transition minus
standard) for the therapy effect is less than 0, then lower
variability in immunosuppressive agent levels and thus
better adherence to therapy due to the new transition
model is therefore proved. Sensitivity analyses will be car-
ried out using multivariate regression models with con-
sideration of additional prognostic factors (modeling after
stepwise variable selection). Secondary dichotomous
endpoints (such as transplant loss) will be assessed with
multivariate logistic regression models.
All patients included in the study (intention-to-treat
population) will be considered in the primary and sec-
ondary analyses described above. For patients who suffer
a transplant loss, the immunosuppressive agent levels
measured before the loss will be used. Using a conserva-
tive approach, patients with fewer than three immuno-
suppressive agent level datum points will be coded with
the largest coefficient of variation (%) in their respective
therapy group. The study began recruiting patients as
from 1 April 2014 (pre-screening).
Discussion
This study will provide fundamental data about medical
care structures in the transition of adolescent nephrol-
ogy patients from pediatric to adult care. It is designed
to test a new transition model using case managementand modern telemedicine. According to the interven-
tions used (case management and smartphone apps),
our randomized controlled trial is an open unblinded
study. This may influence the patient outcomes after 12
and 24 months. However, a blinded design is not pos-
sible in this kind of a trial.
To the best of our knowledge, there are no comparable
randomized prospective studies in the literature. The
major aim of the study is to utilize improved medical
care structures, with the long-term goal of improving
transplant survival and thereby reducing morbidity and
mortality. Upon completion, this study ultimately aims
to establish the Berliner TransitionsProgramm, com-
bined with use of apps, as a medical care standard in the
transition of young patients who have received a kidney
transplant. Once the study has been completed, the apps
will be made available throughout Germany. This work
has the potential to optimize the medical care of adoles-
cents during the critical pediatric-to-adult care transition
phase.
Trial status
Phase I of the study is in progress. Recruitment has
started in November 2014 and is expected to finish in
November 2015. The healthcare currently in place is be-
ing analyzed and the tools to be used in phase II are be-
ing reviewed.
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